Oxatomide inhibits synthesis and release of platelet-activating factor in human neutrophils

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 58, Issue 2, 1998, Pages 99-104

  Shindo, K ^a   Fukumura, M ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FORMYLMETHIONYLLEUCYLPHENYLALANINE; OXATOMIDE; THROMBOCYTE ACTIVATING FACTOR;

ANIMAL CELL; ARTICLE; ASTHMA; CONTROLLED STUDY; GUINEA PIG; HUMAN; HUMAN CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; THROMBOCYTE AGGREGATION;

ANIMALIA; CAVIA PORCELLUS; SUS SCROFA;

EID: 0031888731     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(98)90147-8     Document Type: Article

References (32)

1. Manabe H., Ohmori K., Tomioka H., Yoshida S. Oxatomide inhibits the release of chemical mediators from human lung tissues and from granulocytes. Int Arch Allergy Appl Immunol 1988; 87: 91-97.
2. Ohmori K., Ishii H., Shuto K., Nakamizo N. Pharmacological studies on oxatomide. 4. Effect on the histamine release from rat isolated peritoneal exudate cells (PEC) and lung slices. Folia Pharmacol Jpn 1982; 80: 441-449.
3. Ohmori K., Ishii H., Kubota T., Shuto K., Nakamizo N. Inhibitory effects of oxatomide on several activities of SRS-A and synthetic leukotrienes in guinea-pigs and rats. Arch Int Pharmacodyn 1985; 275: 139-150.
4. Mita H., Shida T. Comparison of anti-allergic activities of the histamine H1 receptor antagonists epinastine, ketotifen and oxatomide in human leukocytes. Arzneim-Forsch 1995; 45: 36-40.
5. Richards D. M., Brogden R. N., Heel R. C., Speight T. M., Avery G. S. Oxatomide. A review of its pharmacodynamic properties and therpeutic efficacy. Drugs 1984; 27: 210-231.
6. Miwa M., Miyake T., Yamaoka T. et al. Characterization of serum platelet-activating factor (PAF) acetylhydrolase: correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J Clin Invest 1988; 82: 1983-1991.
7. Stafforini D. M., Satoh K., Atkinson D. L. et al. PAF acetylhydrolase deficiency: a missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest 1996; 97: 2784-2791.
8. Nadel J. A. Genetics reveals importance of platelet activating factor in asthma and possibly other inflammatory states. J Clin Invest 1996; 97: 2689-2690.
9. Misso N. L. A., Gillon R. L., Taylor M. L., Stewart G. A., Thompson P. J. Acetyl-CoA: lyso-platelet-activating factor acetyltransferase activity in neutrophils from asthmatic patients and normal subjects. Clin Sci 1993; 85: 455-463.
10. Misso N. L. A., Gillon R. L, Stewart G. A., Thompson P. L. Lyso-PAF acetyltransferase activity in neutrophils of patients during acute asthma and after recovery. Eur Respir J 1996; 9: 2243-2249.
11. Shindo K., Koide K., Hirai Y., Sumitomo M., Fukumura M. Priming effect of platelet activating factor on leukotriene C4 from stimulated eosinophils of asthmatic patients. Thorax 1996; 51: 155-158.
12. Shindo K., Koide K., Fukumura M. Platelet-activating factor increases LTB4 release in stimulated alveolar macrophages from asthmatic patients. Eur RespirJ 1997 (in press).
13. Gartner I. Separation of human eosinophils in density gradients of polyvinylpyrrolidone-coated silica gel (Percoll). Immunology 1980; 40: 133-136.
14. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. ScandJ Clin Lab Invest 1968; 21: 77-89.
15. Day R. P. Eosinophil cell separation from human peripheral blood. Immunology 1970; 18: 955-962.
16. Fukuda T., Dunnette S. L., Reed C. E. Ackerman S. J., Peters M. S., Gleich G. J. Increased numbers of hypodense eosinophils in the blood of patients with bronchial asthma. Am Rev Respir Dis 1985; 132: 981-985.
17. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225-244.
18. Pinckard R. N., Farr R. N., Hanahan D. J. Physicochemical and functional identity of rabbit platelet-activating fator (PAF) released in vivo during IgE anaphylaxis with PAF released in vitro from IgE sensitized basophils. J Immunol 1979; 123: 1847-1857.
19. Hanahan D. J., Weintraub S. T. Platelet-activating factor, isolation, identification, and assay. Methods Biochem Anal 1986; 31: 195-219.
20. Shindo K., Fukumura M. Azelastine hydrochloride inhibits platelet activating factor-like activity in human eosinophils. Prostaglandins Leukot Essent Fatty Acids 1996; 55: 217-221.
21. Bligh E. G., Dyer W. J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911-917.
22. Court E. N., Kingston W. P. A sensitive assay for platelet-activating factor using guinea-pig platelets. Br J Pharmacol (proceeding) 1987; 91: 409.
23. Shindo K., Fukumura M., Hirai Y., Koide K. Effect of azelastine hydrochloride on release and production of platelet activating factor in human neutrophils. Prostaglandins Leukot Essent Fatty Acids 1997; 56: 373-377.
24. Ford-Hutchinson A. W. Leukotriene B4 in inflammation. Crit Rev Immunol 1990; 10: 1-12.
25. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science (Wash. DC) 1983; 220: 568-575.
26. Koh Y. Y., Dupuis R., Pollice M., Albertine K. H., Fish J. E., Peters S. P. Neutrophils recruited to the lungs of humans by segmental antigen challenge display a reduced chemotactic response to leukotriene B4. Am J Respir Cell Mol Biol 1993; 8: 493-499.
27. Czarnetzki B. Increased monocyte chemotaxis towards leukotriene B4 and platelet activating factor in patients with inflammatory dermatosis. Clin Exp Immunol 1983; 54: 486-492.
28. O'Flaherty J. T., Wykle R. L., Miller C. H. et al. 1-O-Alkyl-snglyceryl-3-phosphorylcholines: a novel class of neutrophil stimulation. Am J Pathol 1981; 103: 70-79.
29. Achterrath-Tuckermann U., Weischer C. H., Szelenyi I. Azelastine, a new antiallergic/antiasthmatic agent, inhibits PAF-acether-induced platelet aggregation, paw edema and bronchoconstriction. Pharmacology 1988; 36: 265-271.
30. 2) from rat mast cells and guinea-pig lung. Agent Actions 1987; 21: 32-37.
31. Tosaka K., Akagi M., Mio M., Miyoshi K., Nakaya N. Inhibitory effects of oxatomide on intracellular Ca mobilization, Ca uptake and histamine release. Int Arch Allergy Immunol 1987; 83: 348-353.
32. Emanuel M. B., Towse G. D. W. Oxatomide. A new drug combining anti-allergic and anti-spasmogenic properties. Part II: Clinical studies. Drugs of Today 1980; 16: 231-237.